Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 1
2017 2
2018 3
2019 3
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota.
Lomeli BK, Galbraith H, Schettler J, Saviolakis GA, El-Amin W, Osborn B, Ravel J, Hazleton K, Lozupone CA, Evans RJ, Bell SJ, Ochsner UA, Jarvis TC, Baqar S, Janjic N. Lomeli BK, et al. Antimicrob Agents Chemother. 2019 Dec 20;64(1):e01395-19. doi: 10.1128/AAC.01395-19. Print 2019 Dec 20. Antimicrob Agents Chemother. 2019. PMID: 31685472 Free PMC article. Clinical Trial.
A two-part phase 1 study to establish and compare the safety and local tolerability of two nasal formulations of XF-73 for decolonisation of Staphylococcus aureus: A previously investigated 0.5mg/g viscosified gel formulation versus a modified formulation.
Yendewa GA, Griffiss JM, Jacobs MR, Fulton SA, O'Riordan MA, Gray WA, Proskin HM, Winkle P, Salata RA. Yendewa GA, et al. J Glob Antimicrob Resist. 2020 Jun;21:171-180. doi: 10.1016/j.jgar.2019.09.017. Epub 2019 Oct 7. J Glob Antimicrob Resist. 2020. PMID: 31600598 Free PMC article. Clinical Trial.
Safety, Tolerability, Systemic Exposure, and Metabolism of CRS3123, a Methionyl-tRNA Synthetase Inhibitor Developed for Treatment of Clostridium difficile, in a Phase 1 Study.
Nayak SU, Griffiss JM, Blumer J, O'Riordan MA, Gray W, McKenzie R, Jurao RA, An AT, Le M, Bell SJ, Ochsner UA, Jarvis TC, Janjic N, Zenilman JM. Nayak SU, et al. Antimicrob Agents Chemother. 2017 Jul 25;61(8):e02760-16. doi: 10.1128/AAC.02760-16. Print 2017 Aug. Antimicrob Agents Chemother. 2017. PMID: 28584140 Free PMC article. Clinical Trial.
Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults.
Zenilman JM, Fuchs EJ, Hendrix CW, Radebaugh C, Jurao R, Nayak SU, Hamilton RG, McLeod Griffiss J. Zenilman JM, et al. Antiviral Res. 2015 Nov;123:114-9. doi: 10.1016/j.antiviral.2015.09.008. Epub 2015 Sep 25. Antiviral Res. 2015. PMID: 26391974 Free PMC article. Clinical Trial.